BridgeMD
Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Diffuse Large B-Cell Lymphoma
EU CTIS ID: 2024-513616-95-00
What this study is testing
Phase 2: To compare efficacy (ORR - overall response rate) in patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL) treated with Rituximab-Gemcitabine-Dexamethasone-Platinum plus either selinexor 40 mg or selinexor 60 mg to R-GDP alone based on the Lugano 2014 Criteria. Phase 3: To compare Progression-free survival (PFS) in patients with RR DLBCL treated with SR-GDP (selinexor + rituximab, gemcitabine, dexamethasone, platinum) followed by selinexor to PR-GDP (placebo plus rituximab, gemcitabine, dexamethasone, platinum) followed by placebo based on the Lugano 2014 Criteria.
- Phase II and Phase III (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients ≥18 years of age
- An estimated life expectancy of >3 months at Screening
- Patients with primary refractory DLBCL defined as no response or relapse within 6 months after ending first-line treatment will be allowed on study
- Agree to highly effective contraception during the duration of the study with contraception use continuing for 12 months after the last dose of study treatment • Female patients of childbearing potential must have a negative serum pregnancy test at Screening and agree to use highly effective methods of contraception throughout the study and for 12 months following the last dose of study treatment (except patients with non-childbearing potential: Age >50 years and naturally amenorrhoeic for >1 year, or previous bilateral salpingo-oophorectomy, or hysterectomy). • Male patients who are sexually active must use highly effective methods of contraception throughout the study and for 12 months following the last dose of study treatment. Male patients must agree not to donate sperm during the study treatment period and for 12 months following the last dose of study treatment.
- Have pathologically confirmed de novo DLBCL or DLBCL transformed from previously diagnosed indolent lymphoma (e.g., follicular lymphoma). Patients with high grade lymphoma with c-MYC, Bcl-2 and/or Bcl-6 rearrangements are eligible (Phase 2 only) (Documentation to be provided)
- Have received at least 1 but no more than 3 prior lines of systemic therapy for the treatment of DLBCL with relapsed or refractory disease following their most recent regimen (Documentation to be provided) • Salvage chemoimmunotherapy followed by stem cell transplantation will be considered as 1 line of systemic therapy • Maintenance therapy will not be counted as a separate line of systemic therapy • Radiation with curative intent for localized DLBCL will not be counted as 1 line of systemic therapy
You likely can't join if
- DLBCL with mucosa-associated lymphoid tissue (MALT) lymphoma; composite lymphoma (Hodgkin’s lymphoma + non-Hodgkin’s lymphoma [NHL]); DLBCL transformed from diseases other than indolent NHL; primary mediastinal (thymic) large B-cell lymphoma (PMBL); T-cell rich large B-cell lymphoma.
- Previous treatment with selinexor or other XPO1 inhibitors
- Contraindication to any drug contained in the combination therapy regimen (SR-GDP)
- Known active central nervous system or meningeal involvement due to DLBCL at the time of Screening
- Use of any standard or experimental anti-DLBCL therapy (including nonpalliative radiation, chemotherapy, immunotherapy, radio-immunotherapy, or any other anticancer therapy) <21 days prior to Cycle 1 Day 1 (Prednisone <30 mg or equivalent are permitted; palliative radiation is permitted only if on non-target lesions)
- Any AE, by Cycle 1 Day 1, which has not recovered to Grade ≤1 (Common Terminology Criteria for Adverse Events [CTCAE] v5.0), or returned to baseline, related to the previous DLBCL therapy, except hematological abnormalities (per Inclusion criteria #6) and alopecia
See the full eligibility criteria
Who can join
- Patients ≥18 years of age
- An estimated life expectancy of >3 months at Screening
- Patients with primary refractory DLBCL defined as no response or relapse within 6 months after ending first-line treatment will be allowed on study
- Agree to highly effective contraception during the duration of the study with contraception use continuing for 12 months after the last dose of study treatment • Female patients of childbearing potential must have a negative serum pregnancy test at Screening and agree to use highly effective methods of contraception throughout the study and for 12 months following the last dose of study treatment (except patients with non-childbearing potential: Age >50 years and naturally amenorrhoeic for >1 year, or previous bilateral salpingo-oophorectomy, or hysterectomy). • Male patients who are sexually active must use highly effective methods of contraception throughout the study and for 12 months following the last dose of study treatment. Male patients must agree not to donate sperm during the study treatment period and for 12 months following the last dose of study treatment.
- Have pathologically confirmed de novo DLBCL or DLBCL transformed from previously diagnosed indolent lymphoma (e.g., follicular lymphoma). Patients with high grade lymphoma with c-MYC, Bcl-2 and/or Bcl-6 rearrangements are eligible (Phase 2 only) (Documentation to be provided)
- Have received at least 1 but no more than 3 prior lines of systemic therapy for the treatment of DLBCL with relapsed or refractory disease following their most recent regimen (Documentation to be provided) • Salvage chemoimmunotherapy followed by stem cell transplantation will be considered as 1 line of systemic therapy • Maintenance therapy will not be counted as a separate line of systemic therapy • Radiation with curative intent for localized DLBCL will not be counted as 1 line of systemic therapy
- Positron emission tomography (PET) positive measurable disease with at least 1 node having longest diameter (LDi) >1.5 cm or 1 extranodal lesion with LDi >1 cm (per the Lugano 2014 Criteria) (Documentation to be provided). The Deauville 5-point scale (D5PS) score assessed on the FDG PET/CT should be between 3 to 5.
- Not intended for HSCT or CAR-T cell therapy based on objective clinical criteria determined by the treating physician. Patients who cannot receive HSCT due to active disease are allowed on study (up to approximately 15% of patients enrolled in each Phase). Documentation on lack of intention to proceed to receive HSCT or CAR-T therapy must be provided by the treating physician.
- Adequate bone marrow function at screening, defined as (Documentation to be provided): • Absolute neutrophil count ≥1 × 109/L • Platelet count ≥100 × 109/L (without platelet transfusion <14 days prior to C1D1) • Hemoglobin ≥8.5g/dl (without red blood cell transfusion <14 days prior to C1D1)
- Circulating lymphocytes ≤50 × 109/L
- Adequate liver and kidney function, defined as (Documentation to be provided): • Aspartate transaminase (AST) or alanine transaminase (ALT) ≤2.5 × upper limit of normal (ULN), or ≤5 × ULN in cases with known lymphoma involvement in the liver • Serum total bilirubin ≤2 × ULN, or ≤5 ULN if due to Gilbert syndrome or in cases with known lymphoma involvement in the liver • Calculated creatinine clearance (CrCl) ≥30 mL/min based on Cockcroft-Gault formula
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
What rules you out
- DLBCL with mucosa-associated lymphoid tissue (MALT) lymphoma; composite lymphoma (Hodgkin’s lymphoma + non-Hodgkin’s lymphoma [NHL]); DLBCL transformed from diseases other than indolent NHL; primary mediastinal (thymic) large B-cell lymphoma (PMBL); T-cell rich large B-cell lymphoma.
- Previous treatment with selinexor or other XPO1 inhibitors
- Contraindication to any drug contained in the combination therapy regimen (SR-GDP)
- Known active central nervous system or meningeal involvement due to DLBCL at the time of Screening
- Use of any standard or experimental anti-DLBCL therapy (including nonpalliative radiation, chemotherapy, immunotherapy, radio-immunotherapy, or any other anticancer therapy) <21 days prior to Cycle 1 Day 1 (Prednisone <30 mg or equivalent are permitted; palliative radiation is permitted only if on non-target lesions)
- Any AE, by Cycle 1 Day 1, which has not recovered to Grade ≤1 (Common Terminology Criteria for Adverse Events [CTCAE] v5.0), or returned to baseline, related to the previous DLBCL therapy, except hematological abnormalities (per Inclusion criteria #6) and alopecia
- Major surgery <14 days of Cycle 1 Day 1
- Hematopoietic stem cell transplantation/CAR-T therapy as follows: • Autologous HSCT <100 days or allogeneic HSCT <180 days prior to Cycle 1 Day 1 • Active graft-versus-host disease (GVHD) after allogeneic HSCT (or cannot discontinue GVHD treatment or prophylaxis) • CAR-T infusion <90 days prior to Cycle 1
- Neuropathy Grade ≥2 (CTCAE v5.0)
- Any life-threatening illness, medical condition, or organ system dysfunction which, in the Investigator’s opinion, could compromise the patient’s safety, or being compliant with the study procedures
- Uncontrolled (i.e., clinically unstable) infection requiring parenteral antibiotics, antivirals, or antifungals within 7 days prior to first dose of study treatment; however, prophylactic use of these agents is acceptable (including parenteral)
- Patients with active hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infections: • Patients with active HBV are allowed if antiviral therapy for hepatitis B has been given for >8 weeks and viral load is <100 IU/mL prior to first dose of study treatment. • Patients with known history of HCV or found to be HCV antibody positive on screening, are allowed if there is documentation of negative viral load per institutional standard. • Patients with HIV are allowed if they have a negative viral load per institutional standard, and no history of acquired immune deficiency syndrome (AIDS)-defining opportunistic infections in the last year.
- Inability to swallow tablets, malabsorption syndrome, or any other gastrointestinal disease or dysfunction that could interfere with absorption of study treatment
- Breastfeeding or pregnant women
- Inability or unwillingness to sign an informed consent form (ICF)
- In the opinion of the Investigator, patients who are significantly below their ideal body weight
- Patients who received a live attenuated vaccine within prior 28 days of the first dose of study treatment
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.